Diabetic neuropathy was defined at the San Antonio Consensus Conference as “a descriptive term meaning a demonstrable nerve disorder, either clinically evident or subclinical, that occurs in the setting of diabetes mellitus without other causes for peripheral neuropathy. The neuropathic disorder includes manifestations in the somatic or autonomic parts of the peripheral nervous system” [1]. Diabetic neuropathy is a chronic condition caused by hyperglycaemia, characterized by progressive morphological destruction of the peripheral nervous system, accompanied by loss of peripheral nerve function. Clinically, loss of function is defined by distal loss of sensibility, muscular strength and loss of deep tendon reflexes as well as by autonomic dysfunction of viscera and blood vessels.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Consensus statement. Report and recommendation of the San Antonio Conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988;11:592–597.
Pirart J. Diabetes mellitus and its generative complications: A prospective study of 4400 patients observed. Diabetes Care 1978;1:168–188.
DCCT research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
UK Prospective Diabetes Study group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet 1998;352:837–853.
Duby JJ, Campbell RK, Setter SM et al. Diabetic neuropathy: An intensive review. Am J Health Syst Pharm 2004;61:160–173.
Sima AAF, Pierson CR. Pathogenesis and Pathology of diabetic neuropathy. In: Gries FA, editor. Textbook of diabetic neuropathy, Stuttgart. New York: Georg Thieme verlag, 2003, 83–169.
Boel E, Selmer J, Flodgaard HJ et al. Diabetic late complications: Will aldose reductase inhibitors or inhibitors of advanced glycosylation endproducts formation hold promise? J Diab Compl 1995;9:104–129.
Dyck P. Pathology and pathophysiology- Human and experimental. In Dyck PJ, editor. Diabetic neuropathy. London: WB Saunders Company, 1987, 223–237.
Dejgaard A, Gade A, Larsson H et al. Evidence of diabetic encephalopathy. Diabet Med 1991;8:162–167.
Garrow AP, Boulton AJM. Vibration perception threshold- a valuable assessment of neural dysfunction in people with diabetes. Diabet Metab Res Rev 2006;22:411–441.
Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabet Med 1988;15:97–112.
Jensen TS, Backonja M, Jimenez SH et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diabet Vasc Dis Res 2006;3(2):108–119.
Martin CL, Albers J, Herman WH et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006;29:340–304.
Allen RDM, Al-Habri IS, Morris JGL et al. Diabetic neuropathy after pancreas transplantation: determinants on recovery. Transplantation 1997;63:830–838.
Sima AAF. Pathological mechanisms involved in diabetic neuropathy: Can we slow the process? Curr Opin Investig Drugs 2006;7(4):324–337.
Ekberg K, Brismar T, Johansson BL et al. Amelioration of sensory nerve dysfunction by C-peptide in patients with Type 1 Diabetes. 2003;52:536–541.
Obrosova IG, Pacher P, Szab C et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetic complications. Diabetes Nutr Metab. 2005;54:234–242.
Hotta N, Akanuma Y, Kawamori R et al. Long-term clinical effects of Epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. Diabetes Care 2006;29(7):1538–1544.
Bril V, Buchanan RA, Ranistat study group. Long term effects of ranirestat on peripheral nerve function in patients with diabetic sensimotor polyneuropathy. Diabetes Care 2006;29(1):68–72.
Vincent MV, Feldman EL. New insights into the mechanism of diabetic neuropathy. Rev Endocr Metab Disord 2004;5(3):227–236.
The SYDNEY trial. The sensory symptoms of diabetic polyneuropathy are improved with alfa-lipoic acid. Diabetes Care. 2003;26:770–776.
Tankova T, Chernikova S, Koev D. Treatment for diabetic mononeuropathy with alfa-lipoic acid. Int J Clin Pract 2005;59(6):645–650.
Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie Biologie 2006;54:405–419.
Goldin A, Beckman JA, Schmidt AM et al. Advanced glycation end products- sparking the development of diabetic vascular injury. Circulation 2006;114:597–605.
Cameron NE, Eaton SEM, Cotter MA et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44:1973–1988.
Keen H, Payan J, Allawi J. et al. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993;16:8–15.
Apfel SC, Schwartz S, Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284(17):2215–21.
Argoff C, Backonia MM, Belgrade MJ et al. Consensus guidelines: Treatment planning and options. Mayo Clin Proc. 2006;81:s12–s25.
Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diab. 2005;23(1):9–15.
Vinik A. Clinical review: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005;90:4936–4945.
Morello CM, Leckband SG, Stoner CP et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ArchIntern Med 1999;159:1931–1937.
Griesing T, Freeman R Rosenstock et al. Efficacy, safety and tolerability og pregabalin treatment for diabetic peripheral neuropathy: findings from 6 randomized controlled trials. Diabetologia 2005;48 (suppl 1):A351.
Grosskopf J, Mazzola J, Wan J et al. A randomized, placebo controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114:177–180.
Kastrup J, Petersen P, Dejgaard et al. Treatment of chronic diabetic neuropathy with intravenouis lidocaine infusion. Br Med J 1986;292:173–174.
Dejgaard A, Petersen P, Kastrup J. Mexilitine for treatment of chronic diabetic neuropathy. Lancet 1988;29:9–11.
Sindrup SH, Andersen G, Madsen C et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised double blind, controlled trial. Pain 1999;83:85–90.
Jensen PG, Larson R. Management of painful diabetic neuropathy. Drugs and aging. 2001;18(10):737–749.
Vinik AI. Diabetic neuropathies. Med Clin N Am 2004;88:947–999.
Boulton AJM, Vinik AI, Arezo JC et al. Diabetic neuropathies. Diabetes Care 2005;28(4):956–962.
Brownlee M. The pathobiology of diabetic complications – a unifying mechanism. Diabetes 2005;54: 1615–1625.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Dejgaard, A., Hilsted, J. (2007). Pharmacotherapy in Diabetic Neuropathy. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_22
Download citation
DOI: https://doi.org/10.1007/978-0-387-69737-6_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-69736-9
Online ISBN: 978-0-387-69737-6
eBook Packages: MedicineMedicine (R0)